Our solution has undergone significant clinical validation with a multicentric clinical trial in Europe (the EvAI-Fib Trial, JCE 2022).
We are currently conducting an
international randomized clinical trial (the Tailored-AF trial, NCT04702451) to further validate its use for persistent AF.